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A b s t r a c t
Introduction: Gliomas are the most aggressive and common primary tumors 
of the central nervous system (CNS). Many side effects of drugs containing 
platinum and their poor penetration of the CNS are major drawbacks in gli-
oma therapy. The aim of the study was to investigate and compare the tox-
icity of platinum nanoparticles and cisplatin and their anticancer properties 
in examination with a U87 glioma cell line and tumor.
Material and methods: Nanoparticles of platinum (NP-Pt) and cisplatin were 
incubated with U87 glioma cells or injected directly into tumor tissue. The 
biological properties of NP-Pt and cisplatin were compared through the mor-
phology, viability, mortality, genotoxicity and the type of cell death of U87 
glioma cells, the morphology and ultrastructure of glioma tumor, and ex-
pression of caspase-3, p53 and PCNA mRNA. 
Results: NP-Pt at concentrations of 0.14 µM/ml, 0.29 µM/ml and 0.65 µM/ml 
had a harmful influence on viability of U87 glioblastoma multiforme (GBM) 
cells, but also showed genotoxic properties as well as a pro-apoptotic effect 
on cancer cells. It was found that NP-Pt decreased the weight and volume 
of U87 GBM tumor tissue and caused pathomorphological changes in the 
ultrastructure and morphology of tumor tissue, but they also upregulated 
p53 and caspase-3 mRNA expression.
Conclusions: The comparison between the effectiveness of glioblastoma 
treatment by NP-Pt vs cisplatin showed promising results for future studies. 
The results indicate that the properties of NP-Pt might be utilized for brain 
cancer therapy.
Key words: platinum nanoparticles, U87, glioblastoma, genotoxicity, 
apoptosis, cancer.
Introduction
Glioblastoma multiforme (GBM) is one of the most aggressive (WHO 
grade IV) neoplastic malignant tumors of the central nervous system. 
Malignant brain tumors are very progressive and, despite developments 
in neurosurgery and the strategy of chemotherapy and radiotherapy, 
the effectiveness of treatment is unfavorable [1]. Chemotherapy based 
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on platinum compounds is most effective, but 
only increases the survival time of patients diag-
nosed with GBM [2, 3]. Cisplatin is a cytostatic and 
DNA-damaging drug that is widely used in first-
line systemic chemotherapy against epithelial ma-
lignancies and in the second- and third-line treat-
ment strategies against metastatic malignancies, 
including malignant GBM [4]. The mechanism of 
action of Pt-based drugs involves cell cycle arrest 
[5, 6] caused by DNA damage by Pt2+ ions, which 
attach to N7 sites of DNA guanine bases and, after 
hydrolysis of Pt-Cl bonds, the cross-links in DNA are 
formulated [7, 8]. However, the major drawbacks 
of cisplatin are the dose-dependent side effects 
[9–12] and the drug resistance of GBM [4, 13]. The 
new GBM treatment strategies are based on the 
activation of the programmed cell death pathways 
by antineoplastic agents, including drugs, antibod-
ies, bioactive molecules and nanoparticles [14]. 
Moreover, it is also very important to verify the an-
ticancer properties of new types of bioactive mole-
cules in in vivo models. The chicken embryo model 
is a suitable model to evaluate the effect of new 
molecules in cancer diseases and angiogenesis but 
also for neurotoxicity studies because at 15 days 
of incubation the blood brain barrier (BBB) is fully 
functioning [15]. The main function of the BBB is 
the protection of the brain tissue from substances 
harmful for the bloodstream. However, in cancer 
chemotherapy the impermeability of the BBB has 
an adverse impact and creates a  highly specific 
barrier to antineoplastic drugs [16]. Furthermore, 
the induction of human gliomas or other types of 
tumor growth at the chorioallantoic membrane of 
chicken embryo creates permanent exposure to 
nanoparticles or drug activity without the possibil-
ity to remove them from the organism. 
Nanoparticles of platinum (NP-Pt) have unique 
physiochemical and biological [11] features with 
regard to their small size (< 25 nm), metal struc-
tures (Pt0), large surface area to mass ratio [17], 
catalytic activity and high reactivity [18]. NP-Pt 
may also have different biochemical properties 
than platinum-based antineoplastic drugs after 
administration into an organism, because they are 
a very limited source of ions, and consequently the 
interaction of Pt(0) with body fluids is significantly 
restricted. The potential toxic effects of NP-Pt were 
evaluated in in vitro healthy cells such as human 
[19] or chicken erythrocytes [20] and in ovo studies 
[11], but these biological effect where determined 
by nanosize of particles [21]. The results of these 
studies did not show harmful effects on human red 
blood cells or in general health indices of a chicken 
embryo model. On the other hand, it has also been 
demonstrated that, in MCF-7 and HepG-2 cancer 
cells, NP-Pt, synthesized from K2PtCl6, had dose-de-
pendent toxicity [22]. Moreover, the combination 
of radiation and administration of NP-Pt in hadron 
cancer therapy increased the lethal DNA damage 
by double-strand breaks in HT29 cancer cells [24]. 
Lethal damage of DNA can be caused by inter-
action of NP-Pt coated with OH with phosphate 
groups of DNA, but the direct pathway remains un-
known [6]. Although NP-Pt are also able to induce 
cell cycle arrest by release of Pt2+ ions after H2O2 
generation in endosomes and cause cell apoptosis 
[5, 23, 24], the introduction of NP-Pt into U87 GBM 
tissue has still not been documented. 
We hypothesized that because of their physi-
cochemical and biological properties, NP-Pt may 
be used in GBM cancer therapy. Consequently, the 
objective of this study was to determine potential 
anticancer effects of NP-Pt, with emphasis on the 
mechanisms of apoptosis, using GBM cells in in 
vitro and in vivo experiments.
Material and methods
Preparation and characterization of NP-Pt 
and cisplatin
Cisplatin (cis-diamineplatinum (II) dichloride) 
was obtained from Sigma (479306; Sigma, St. Lou-
is, MO, USA) and diluted to 100X as a stock solu-
tion in ultrapure Milli-Q water. The hydrocolloid of 
nanoparticles of platinum (NP-Pt, high-purity met-
al 99.9999%) was purchased from Nano-koloid 
(Warsaw, Poland). The shape and size of the NP-
Pt were inspected using a JEM-1220 (JEOL, Tokyo, 
Japan) transmission electron microscope (TEM) at 
80 KeV with a  Morada 11-megapixel camera 
(Olympus Soft Imaging Solutions, Münster, Germa-
ny). Samples for the TEM were prepared according 
to the scientific protocol described by Prasek et al. 
[11]. The zeta potential in water was measured 
using a Zetasizer Nano ZS model ZEN3500 (Mal-
vern Instruments, Malvern, UK).
Cell cultures and treatments
The human glioblastoma U87 cell line was 
obtained from the American Type Culture Col-
lection (Manassas, VA, USA) and maintained 
in Dulbecco’s modified Eagle’s culture medium 
supplemented with 10% fetal bovine serum (Sig-
ma-Aldrich), 1% penicillin and streptomycin (Sig-
ma-Aldrich) at 37°C in a humidified atmosphere 
of 5% CO2/95% air in a NuAire DH AutoFlow CO2 
Air-Jacketed Incubator (Plymouth, MN, USA). The 
U87 cells were incubated in a culture dish and cul-
tivated for 24 h for all types of in vitro studies. 
NP-Pt (0.14 µM/ml; 0.29 µM/ml; 0.65 µM/ml) and 
cisplatin (0.22 µM/ml; 0.44 µM/ml, 1 µM/ml) were 
added to the cells separately. The concentration of 
NP-Pt was equal to the atomic mass of Pt atoms 
in cisplatin and based on published data about an-
ticancer properties of cisplatin [25]. Cells cultured 
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without the addition of nanoparticles or cisplatin, 
but with the same volume of Milli-Q water, were 
used as the control group.
Cell morphology
After 24 h of exposure to the nanoparticles or 
cisplatin, the medium was removed and the cells 
were stained using the May-Grünwald-Giemsa 
(Sigma-Aldrich) method, and their morphology 
was investigated using a CKX 41 light microscope 
(Olympus, Tokyo, Japan). Images were captured 
using a ProgRes c12 camera (Jenoptik, Jena, Ger-
many).
Examination of U87 GBM cell ultrastructure 
by TEM
After 24 h of exposure to the nanoparticles, the 
medium was removed and the cells (5 × 103 cells 
per well/six well plates) were collected and under-
went the procedure described by Jaworski et al. [26].
Cell viability assay
The cell viability was evaluated using a 2,3-bis-
(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazoli-
um-5-carboxanilide salt (XTT)-based cell viability 
assay kit (Life Technologies, Taastrup, Denmark). 
U87 cells were incubated in 96-well plates (5 × 103 
cells per well) with hydrocolloids of nanoparticles 
of NP-Pt and cisplatin at the same concentration 
as for the cell morphology assay. In the next step, 
the XTT solution was added to each well and in-
cubated for an additional 3 h at 37°C. The opti-
cal density (OD) of each well was recorded at 
450 nm on a scanning multi-well spectrophotom-
eter (Infinite M200, Tecan, Durham, NC, USA). Cell 
viability is expressed as the percentage (ODtest – 
ODblank)/(ODcontrol – ODblank), where “ODtest” 
is the optical density of cells exposed to NP-Pt and 
cisplatin, “ODcontrol” is the optical density of the 
control sample, and “ODblank” is the optical den-
sity of wells without GBM cells.
Genotoxic assay – comet assay
The genotoxicity of NP-Pt and cisplatin was 
evaluated using single-cell gel electrophoresis 
(the comet assay). U87 cells were incubated for 
24 h in six-well plates (1 × 106 cells per well). NP-Pt 
(0.29 µM/ml) and cisplatin (0.44 µM/ml) were in-
troduced to the cells separately. All the treatment 
groups were triplicate. Cells grown without the 
addition of nanoparticles were used as the con-
trol group. After 24 h of exposure to NP-Pt and 
cisplatin, the cells were collected and evaluated 
according to the modified procedure described by 
Hinzmann et al. [27]. The comets were stained us-
ing 50 µl of 4′,6-diamidino-2-phenylindole (DAPI; 
Sigma) and viewed using a CKX 41 epifluorescent 
inverted microscope with a fluorescent filter, and 
the image was captured with a ProgRes c12 cam-
era. At least 50 cells per group were randomly se-
lected, photographed, and analyzed using Comet 
Assay Software Project software recommended by 
Końca et al. [28]. 
Apoptosis assay
Apoptosis was evaluated using the Alexa Flu-
or 488 Annexin V/Dead Cell Apoptosis Kit with 
Alexa Fluor 488 Annexin V and propidium iodide 
(PI) for flow cytometry (Life Technologies). U87 
GBM cells (1 × 105 cells per well) were incubat-
ed for 24 h. Then the medium was removed, and 
NP-Pt (0.29 µM/ml) and cisplatin (0.44 µM/ml) in 
the culture medium were added to the cells and 
incubated for an additional 24 h. The positive con-
trol was prepared as described by Jaworski et al. 
[26]. U87 cells were harvested, washed in cold 
PBS and transferred to tubes and stained with the 
Annexin V/PI staining protocol (Life Technologies). 
U87 GBM cells were analyzed by flow cytometry 
(FACSCalibur, Becton Dickinson, Franklin Lakes, 
NJ, USA), measuring the fluorescence emission at 
530 nm and 575 nm (or equivalent) using exci-
tation at 488 nm. The positive cells were identified 
on the basis of the fluorescence intensity of An-
nexin V-Alexa Fluor 488 (early stage of apoptosis) 
or PI (end stage of apoptosis and necrosis). Data 
were analyzed using Cell Quest Pro software (Bec-
ton Dickinson), and the regions were set on the 
basis of positive and negative control samples. 
Culture of GBM on chorioallantoic 
membranes
The fertilized eggs (Gallus gallus; n = 60) were 
supplied by a commercial hatchery (Debowka, Po-
land). After 6 days of egg incubation, the silicone ring 
with the deposited 3–4 × 106 U87 cells suspended 
in 30 µl of culture medium was placed on the cho-
rioallantoic membrane according to the procedure 
of Grodzik et al. [29]. The eggs were incubated for 
7 days, and then 36 eggs with visible tumor devel-
opment were chosen. Eggs were divided into three 
groups of 12: the control group, the NP-Pt group 
(8.45 µM/ml) and the cisplatin group (13 µM/ml). 
The eggs were injected with 200 µl of solutions of 
NP-Pt and cisplatin, as proposed by Cemazar et al. 
[30]. The solutions were added directly into the tu-
mors. The concentration of NP-Pt was equal to the 
atomic mass of Pt atoms in cisplatin. After 2 days, 
the tumors were resected for further analysis.
Calculation of tumor volume
Digital images of tumors were taken by a ste-
reomicroscope (SZX10, CellD software version 3.1; 
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Olympus Corporation, Tokyo, Japan). The measure-
ments of volume were taken with cellSens Dimen-
sion Desktop version 1.3 (Olympus). The tumor 
volumes were calculated with the equation:
V = 4 pr3
      
3 ,
 
where r = 1   diameter 1 × diameter 2, p = 3.1415
     
2
. 
Examination of U87 GBM tissue 
morphology
The tumor tissues from control, NP-Pt and cis-
platin treated groups were sampled and fixed in 
10% buffered formalin (pH 7.2). Fixed samples 
were dehydrated in a  graded series of ethanols, 
embedded in Paraplast, and cut into 5 µm sec-
tions using a  microtome (Leica RM 2265, Leica, 
Nussloch, Germany). The morphology of the chick-
en brains was examined using hematoxylin-eosin 
(H + E) staining.
Examination of U87 GBM tumor tissue 
ultrastructure by TEM
For the evaluation of ultrastructure of tumor 
tissues from the control, NP-Pt and cisplatin 
group samples were fixed for TEM in fixative con-
sisting of 1% glutaraldehyde in PBS at pH 7.2. Af-
ter fixation, the tumor tissues were post-fixed in 
1% osmium tetroxide and dehydrated in a grad-
ed series of ethanol. The pellets were embedded 
in a mixture of Araldite and Epon. Ultrathin sec-
tions (100 nm) were cut on an ultramicrotome 
(EM UC6, Leica). 
mRNA expression of caspase-3, p53  
and PCNA
Gene expression at the mRNA level was mea-
sured in tumor tissue samples treated with NP-Pt 
or cisplatin using quantitative polymerase chain 
reaction (PCR). The tissue tumor samples were 
homogenized in TRIzol reagent (Invitrogen, Carls-
bad, CA, USA) using TissueLyser II (Qiagen, Venlo, 
Netherlands), and total RNA was extracted ac-
cording to the manufacturer’s instructions. The 
RNA samples were purified using the SV Total 
RNA Isolation System (Promega, Fitchburg, WI, 
USA). The total RNA concentration was quantified 
using a  NanoDrop ND 1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, DE, USA). 
For each sample, 200 ng of total RNA was reverse 
transcribed using reverse transcriptase (Promega, 
Madison, WI, USA), oligo-dT and random prim-
ers (TAG Copenhagen A/S Symbion, Copenhagen, 
Denmark). The real-time PCR was performed with 
cDNAs and gene-specific primer pairs (TAG Copen-
hagen A/S Symbion; Table I) using SYBR Green 
I detection and the LightCycler System 480 SYBR 
Green I Master (Roche Diagnostics, Basel, Switzer-
land). The samples were denatured for 5 min at 
95°C, amplified using 45 cycles of 10 s at 95°C (de-
naturation), 10 s at 60°C to 62°C (annealing) and 
9 s at 72°C (elongation), followed by quantifica-
tion. All reactions were performed in triplicate. For 
all analyses, relative quantification was applied, 
and the housekeeping genes were b-actin (ACTB) 
and elongation factor 1 a2 (EEF1A2).
Confocal immunofluorescent analysis  
of p53 and caspase-3 protein level
For the confocal immunofluorescent analysis, 
gliomas tissue samples were frozen in Jung Tissue 
Freezing Medium (Leica, Wetzlar, Germany) in liq-
uid nitrogen and cut into 5 µm thick sections us-
ing a cryostat (CM 1900, Leica, Wetzlar, Germany). 
The sections were attached to poly-l-lysine coated 
microscope slides. Tissue was washed with PBS 
and permeabilized with 0.5% Tween 20 (Sigma, 
St. Louis, USA) PBS solution for 10 min. The sec-
tions were blocked with PBS containing 2% goat 
serum and 1% bovine serum albumin (Sigma, St. 
Louis, USA) for 30 min. Sections were incubated 
with primary antibody rabbit anti caspase-3 anti-
body (269518, Novus Biologicals, LLC, Southpark 
Way, CO, USA) and mouse anti-p53 (PAb 240, No-
vus Biologicals) diluted in 2% goat serum (produc-
er recommended dilution) for 12 h at 4°C. After 
caspase-3 and p53 localization in glioma tumor 
tissue, washed sections were incubated with sec-
ondary antibody: for caspase-3 goat anti-rabbit 
Atto 488 conjugate (Cell Signaling Technology, 
Danvers, USA) and for p53 goat anti-mouse FITC 
488 conjugate (Sigma, St. Louis, USA) for 2 h, 
diluted according to the producer’s instructions. 
Nuclei were stained by incubation with 4′,6-di-
Table I. Primer sequences for the investigated genes
Target gene Forward primer Reverse primer
Caspase-3 CAAACTTTTTCAGAGGGGATCG GCATACTGTTTCAGCATGGCAC
p53 GTTCCGAGAGCTGAATGAGG TTATGGCGGGAGGTAGACTG
PCNA AGGCACTCAAGGACCTCATCA GAGTCCATGCTCTGCAGGTTT
EEF1A2 AGCAGACTTTGTGACCTTGCC TGACATGAGACAGACGGTTGC
ACTB GTCCACCTTCCAGCAGATGT ATAAAGCCATGCCAATCTCG
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amidino-2-phenylindole (DAPI) solution for 15 
min (Sigma, St. Louis, USA). After washing the 
coverslips were mounted on slides with Fluoro-
mount mounting medium (Sigma, St. Louis, USA) 
and observed on a IX 81 FV-1000 confocal micro-
scope (Olympus Corporation, Tokyo, Japan). Image 
analysis in confocal mode, Nomarski interference 
contrast, and cell counting were performed using 
FVIO-ASW ver. 1.7c software (Olympus Corpora-
tion, Tokyo, Japan). Three-dimensional images 
were assembled from 30 optical sections.
Statistical analysis
Data were analyzed using one-way analysis 
of variance (ANOVA) with Statgraphics Plus 4.1 
(StatPoint Technologies, Warrenton, VA, USA). The 
differences between groups were tested using 
Tukey’s multiple range tests. All mean values are 
presented with the standard deviation.
Results
Characterization of NP-Pt
NP-Pt had a regular round shape, and the diam-
eter of the particles ranged from 2 nm to 19 nm 
(Figure 1). Agglomeration of NP-Pt colloids was 
not detected. The mean zeta potential of NP-Pt 
was –27.86.
Cell morphology
U87 GBM cells from the control group had the 
characteristic morphology with long branched 
protrusions. Compared to the control, the results 
showed that NP-Pt (0.14 µM/ml; 0.29 µM/ml; 0.65 
µM/ml) and cisplatin (0.22 µM/ml; 0.44 µM/ml; 
1 µM/ml) treatment decreased the number of cells 
and reduced the length of cell protrusions (Figure 2).
Cell ultrastructure
U87 GBM cell ultrastructure assays showed 
that NP-Pt and cisplatin treatments affected mi-
tochondrial structure, causing deformation of the 
inner membrane and cristae (Figure 3). NP-Pt in-
duced the vacuolization process and degradation 
of the structure of the cytoskeleton of the GBM 
Figure 1. TEM images of NP-Pt. Scale bar: 100 nm
Figure 2. Morphology of U87 glioma cells. A – un-
treated cells (control group), B – cells treated with 
NP-Pt (0.29 µM/ml), and C – cisplatin treated cells 
(0.44 µM/ml). Black arrows point to cells with in-
correct morphology. May-Grünwald staining meth-
od. Light optical microscopy. Scale bars: 40 µm
A B
C
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cells. Compared to the cells treated with cisplatin, 
the TEM images of cells treated with nanoparticles 
showed that NP-Pt have strong affinity to mito-
chondria (Figure 3).
Cell viability 
The XTT cell viability assay is based on the 
ability of living and metabolically active cells to 
reduce the tetrazolium salt XTT into the orange 
formazan product. The results showed that GBM 
cells treated with NP-Pt and cisplatin had de-
creased metabolic activity compared to the un-
treated GBM cells. Furthermore, increased con-
centration of NP-Pt resulted in linear decreased 
cell vitality at a comparable level to cisplatin (Fig-
ure 4). 
Genotoxic activity of NP-Pt as determined 
by the comet assay
Genotoxic activity assessed by the comet as-
say (Figure 5) showed formation of comets in cells 
treated with NP-Pt (0.29 µM/ml) and cisplatin 
(0.44 µM/ml). In contrast, cells from the control 
group did not form any comets (Figure 5). The lev-
el of genotoxicity of NP-Pt and cisplatin, illustrat-
ed by tail DNA percentage, was not significantly 
different (Figure 5).
Apoptosis assay
The annexin V/PI a ssay is an effective method 
for detecting the type of cell death by detecting 
the location of phosphatidylserine on cell mem-
branes. The detection process is possible by moni-
toring the phosphatidylserine location by annexin 
V, which has a strong and specific affinity to phos-
phatidylserine. NP-Pt and cisplatin treatments of 
U87 GBM cells increased the amount of cell death 
and induced apoptosis (Figure 5). The level of 
apoptosis-positive cells was higher after cisplatin 
A
C
B
D
Figure 3. TEM evaluation of U87 glioma cells. A – untreated cells (control group), B and C – U87 cells treated with 
0.29 µM/ml of NP-Pt, D – U87 cell treated with 0.44 µM/ml of cisplatin
M – mitochondria, V – vacuoles. Black arrows – point to complexes of DNA and NP-Pt (C) or cisplatin (D). White arrows point to 
cytoskeleton deformation. A, B, D scale bars – 500 nm, C scale bar – 200 nm.
Figure 4. Cell viability – XTT assay. Effect of NP-Pt 
(black bars) and cisplatin (grey bars), and untreated 
cells (white bars) on the viability of U87 glioma cells
The columns with different letters a,b,c,dindicate significant 
differences between the concentrations (p < 0.05).
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Figure 5. Genotoxic and proapoptotic properties of NP-Pt. A, B, C – comets from single-cell gel electrophore-
sis stained with DAPI (4′, 6-diamidino-2-phenylindole). A – untreated U87 cells, and treated with: B – platinum 
nanoparticles (0.29 µM/ml), C – cisplatin (0.44 µM/ml). Scale bars 500 µm. D – Tail DNA percentage. C – untreated 
U87 cells and treated with NP-Pt – platinum nanoparticles and cisplatin. D – the columns with different letters a,b 
indicate significant differences between groups (p < 0.05). Flow cytometry Annexin V-Alexa Fluor 488 and propid-
ium iodide (PI) assay: E – scatter diagrams of U87 GBM cells exposed to platinum nanoparticles (0.29 µM/ml) and 
cisplatin (0.44 µM/ml). F – Rate of necrosis (blue bars) and apoptosis (red bars) in U87 GBM cells
Control group – untreated cells, NP-Pt – platinum nanoparticles.
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treatment (58%) than after the NP-Pt treatment 
(51%). The degree of necrosis was the highest 
in GBM cells after cisplatin treatment, while the 
number of necrotic cells after NP-Pt was lower 
(Figure 5). 
GBM tumor tissue – volume, weight  
and morphology after treatment with NP-Pt 
and cisplatin
The GBM cells were cultivated on chorioallan-
toic membranes. After resection of tumor tissue, 
the volume, weight and morphology were com-
pared. NP-Pt and cisplatin treatments significantly 
decreased the volume and weight of tumors com-
pared to the control group. There were no differenc-
es between treatment groups (Table II, Figure 6). 
The evaluation of the cross section of glioma tu-
mor tissue stained by the H + E method showed 
that after NP-Pt injection the cell density was de-
creased and the tumor lost the compact structure 
of the tissue. Comparing the efficiency of anti-
cancer properties of NP-Pt vs. cisplatin, after the 
cisplatin treatment the morphology of tumor tis-
sue showed the higher density of cells (Figure 6). 
Moreover, the cross section of tumor tissue also 
showed the typical presence of various types of 
cells: large, small, multinuclear cells and cells with 
atypical morphology of nuclei. 
GBM tumor ultrastructure
The GBM tumor examination of ultrastructure 
by TEM showed that NP-Pt had a toxic effect on 
tissue structure causing deformation of the mi-
tochondrial inner membrane and also interacting 
with mitochondria genetic materials (Figure 7). 
Moreover, NP-Pt were present on the mitochon-
drial membrane. TEM images showed that NP-Pt 
treatment also had an impact on the vacuolization 
process of tumor GBM tissue. 
mRNA expression of caspase-3, p53 and 
PCNA
The level of mRNA expression of caspase-3 in-
creased after the NP-Pt and cisplatin treatments 
of the U87 GBM tumor (Table III). The differences 
were significant compared to the control group, 
but were not different between NP-Pt and cispla-
tin. Similar results were observed for p53 mRNA 
expression. The level of mRNA expression of 
caspase-3 and p53 showed that intratumoral in-
jection of NP-Pt and cisplatin induced the apop-
tosis pathway of the GBM tumor. The level of cell 
proliferation was verified by evaluation of PCNA 
mRNA expression, which showed a  tendency to-
wards decreasing PCNA expression after both 
treatments compared to the control group.
Confocal microscopy – p53 and caspase-3 
protein level
The investigation of p53 protein level in a cross 
section of glioma tumor tissue showed signifi-
cantly increased expression of p53 observed in 
cytoplasm and nuclei stained with p53 antibody 
conjugated with FITC (Figure 8 A). Similar find-
ings were observed after evaluation of caspase-3 
protein level (Figure 8 B). Cisplatin treatment of 
glioma tumor also increased the p53 as well as 
caspase-3 protein level in U87 glioma tissue. 
Discussion
The results of our studies indicate that NP-Pt 
decreased the U87 GBM cell viability. Further-
more, the treatment with NP-Pt was compared to 
cisplatin, and the effectiveness of the treatments 
did not differ significantly despite the same dose 
of Pt2+ ions in cell treatment. The new perspective 
of usage in cancer treatment of platinum nanopar-
ticles programmed to activate the cell death path-
ways are promising for patients diagnosed with 
cancer diseases. However, without the proper 
diagnostic tools, including innovative molecular 
imaging of brain tumor, the treatment strategy 
may be inefficient [31, 32]. Molecular evaluation 
of gliomas can also maximize treatment efficacy, 
decrease the gap between the primary in vitro 
and preclinical in vivo research, and can help to 
improve the anticancer properties of molecules 
against selected types of cells [33]. The NP-Pt 
treatment results confirmed the previous report 
[5] about the interaction of human cells with NP-
Pt, in which nanoparticles also entered the cells, 
decreasing the metabolic activity and inducing cell 
death. The present results are in line with studies 
with different types of cancer cells that demon-
Table II. Characteristics of glioblastoma multiforme U87 tumors treated with NP-Pt and cisplatin
Parameter Group ANOVA
C NP-Pt Cisplatin P-value SE-pooled
Volume [mm3] 92.8a 43.5b 53.9ab 0.002 73.67
Weight [mg] 103.3a 60.4b 41.9b 0.002 22.01
a,bValues within rows with different superscripts are significantly different. U87 glioma tumors treated with platinum nanoparticles 
(NP-Pt 0.29 µM/ml) and cisplatin (0.44 µM/ml), and control (untreated tumor). C – control group, NP-Pt – platinum nanoparticles, ANOVA 
– analysis of variance, SE – standard error. 
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Table III. Caspase-3, p53, and PCNA gene expression profile in glioblastoma multiforme tumors following platinum 
nanoparticles (NP-Pt) and cisplatin treatment
Level of mRNA  
expression
Groups ANOVA SE-pooled
Control NP-Pt Cisplatin P-value
Caspase-3/EEF1A2 0.437a 1.035b 0.950b 0.012 0.107
p53/EEF1A2 0.345a 0.754b 0.589ab 0.004 0.056
PCNA/EEF1A2 0.744 0.554 0.673 0.147 0.066
a,bValues within rows with different superscripts are significantly different, p < 0.05. Values were normalized to the housekeeping gene 
EEF1A2. NP-Pt – platinum nanoparticles, ANOVA – analysis of variance, SE – standard error.
A
C
B
D
Figure 7. TEM evaluation of U87 glioma tumors. A – untreated tumors (control group), B and C – U87 tumors 
treated with 8.45 µM/ml of NP-Pt, D – U87 tumors treated with 13 µM/ml of cisplatin
M – mitochondria, V – vacuoles, GA – Golgi apparatus, ER – endoplasmic reticulum, G – glycogen. Black arrows – point to complexes 
of DNA and NP-Pt (C). White arrows point to mitochondrial deformation. A, B, D scale bars: 500 nm, C – scale bar: 200 nm.
strated decreased viability of cells treated with 
NP-Pt [22–24, 34, 35]. 
The evaluation of the ultrastructure of U87 
GBM cells showed that NP-Pt were able to cross 
the cell membrane, penetrate the cell body and 
adhere especially to mitochondria. These results 
partly confirmed previous findings, demonstrat-
ing that NP-Pt were able to cross HT29 cell mem-
branes, but the cellular localization of NP-Pt was 
different, as nanoparticles were located mainly in 
the cytoplasm [23]. In our studies, NP-Pt were lo-
cated close to nucleic acids, which might encour-
age platinum–DNA chemical reactions. One of the 
treatment strategies of GBM, based on cisplatin, 
involves DNA damage by formation of DNA intra- 
and inter-strand breaks and activation of the cell 
death pathway [7, 33]. However, drug resistance 
of gliomas [2] and side effects of platinum-based 
drugs including hepatotoxicity, ototoxicity and 
nephrotoxicity are major drawbacks in GBM ther-
apy [4, 7, 8]. It has been reported that NP-Pt did 
not show harmful effects on general health after 
administration into an organism [11]. Moreover, in 
our studies, not only was the phenomenon of af-
finity of NP-Pt to DNA observed, but also the geno-
toxic properties of NP-Pt were verified. The pres-
ent results of genotoxicity evaluation based on 
the tail DNA length of formulated comets showed 
that NP-Pt, as well as cisplatin at the same con-
centration of Pt, caused lethal damage of DNA. In 
addition, DNA destruction can also be the result 
of the formation of DNA double-strand breaks by 
Pt2+ ions released from NP-Pt [24]. The results also 
demonstrated that the lethal DNA damage of U87 
GBM cells induced apoptosis. The investigation of 
NP-Pt apoptotic properties showed that U87 GBM 
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Figure 8. Protein expression level of p53 and caspase-3. Visualization of p53 (A, B, C) and caspase-3 (D, E, F) in 
glioblastoma tumors, shown as an overlaid image of 4′,6-diamidino-2-phenylindole-stained nuclei (blue (A1, B1, 
C1, D1, E1, F1)) and cytoplasm p53 stained with fluorescent secondary antibody 488 FITC (green) (A2, B2, C2), and 
caspase-3 stained with fluorescent secondary antibody 488 Alexa Fluor (green) (D2, E2, F2), in the cross-section of 
the tumors, visualized using a confocal microscope
A1-3, D1-3 – control group, B1-3, E1-3 – nanoparticles of platinum, C1-3, F1-3 – cisplatin. Scale bars: 100 µm.
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cells treated with NP-Pt underwent apoptosis at 
a significantly higher level than those treated with 
cisplatin. Introducing NP-Pt to the U87 GBM cells 
also showed that the level of necrosis was low-
er than in the cisplatin-treated cells. Moreover, 
the significantly increased expression of p53 and 
a  tendency towards decreasing PCNA expression 
by NP-Pt treatment of human cells caused inhibi-
tion of the cell cycle and induced apoptosis path-
ways [5]. 
To assess the potential anticancer properties 
of NP-Pt the in ovo U87 tumor model was adopt-
ed. The volume and weight of the tumor were 
significantly reduced compared to the untreated 
tumor. Moreover, the morphology of a cross sec-
tion of tumor tissue showed decreased density 
of tumor cells, pointing to potential anticancer 
properties of NP-Pt. Similar results were obtained 
with the C6 GBM tumor treated with H2PtCl6/TiO2 
nanoparticles, where reduction of tumor weight 
and decreased aggressiveness were detected [6]. 
However, the effect of NP-Pt treatment of the U87 
GBM tumor changed not only the morphology of 
the tumor tissue but also the degradation of mi-
tochondria, and increased the number of vacuoles 
in the tumor tissue. The number of changed struc-
tures visualized in the U87 GBM ultrastructure 
confirms the in vitro results, indicating the induc-
tion of GBM cell death by NP-Pt. In addition, the 
upregulation of mRNA and increased protein ex-
pression level of caspase-3 and p53 by the NP-Pt 
treatment also indicated activation of apopto-
sis in GBM tumor tissue. The expression of p53 
and caspase-3 protein were observed at the cross 
section of gliomas tumors from the control group. 
However, expression of p53 protein was also ob-
served in the nuclei and cytoplasm of tumor cells. 
These results are related to genetic modification 
of the wild type of p53 protein in glioblastoma. 
Moreover, these results confirmed the previously 
demonstrated accumulation in the cytoplasm of 
the wild type p53 in breast carcinomas, gliomas 
and undifferentiated neuroblastomas [36–38]. 
However, the differences between the expres-
sion level at mRNA and protein levels of p53 and 
caspase-3 might be associated with different sen-
sitivity of the methods. The evaluations of mRNA 
expression level are quantitative and qualitative 
techniques, while the protein expression analyses, 
like immunofluorescent staining, are only qualita-
tive. The obtained results confirm previous find-
ings concerning C6 GBM cell death by activation 
of an apoptotic mechanism instead of necrosis [6]. 
Moreover, the present results are in accordance 
with previously demonstrated anticancer prop-
erties of NP-Pt against cancer cell lines including 
HepG2, MCF-7 and HT29, where nanoplatinum 
caused lethal DNA damage of cells and induced 
apoptosis [22–24].
In conclusion, the U87 glioma cells treated with 
NP-Pt showed morphological deformations, DNA 
damage, and decreased metabolic activity, and also 
showed genotoxic effects. Moreover, the observed 
activation of apoptosis was higher after the NP-Pt 
compared with cisplatin treatment of U87 GBM. 
The in ovo studies showed that NP-Pt treatment 
decreased the weight and volume of tumors. Com-
paring the NP-Pt with cisplatin treatment, NP-Pt 
showed direct interaction with mitochondria, but 
also activation of the molecular apoptosis pathways, 
as observed by upregulation of caspase-3 and p53 
gene expression. Consequently, NP-Pt have strong 
anticancer properties, but potential side effects 
must be elucidated in in vivo follow-up research. 
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